NUS reports oral fish vaccine advance against nervous necrosis virus
Bottom line
National University of Singapore researchers, working with Temasek Life Sciences Laboratory, reported a new oral vaccine platform for nervous necrosis virus, or NNV, a major aquaculture pathogen that can cause very high mortality in larval and juvenile fish. The vaccine packages virus-like particles made from the NNV capsid protein inside Lactococcus lactis, a food-grade bacterium, and delivers the material through feed rather than individual injection. In the team’s February 2026 Fish & Shellfish Immunology paper, oral vaccination with sodium hypochlorite-inactivated L. lactis produced about twofold higher antibody and neutralizing antibody titers than purified virus-like particles alone, and cut brain viral load by roughly 2.5 logs, or about 300-fold, seven days after challenge in Asian seabass fingerlings. (newswise.com)
Why it matters: For veterinary professionals working in aquaculture, the advance is less about a single fish vaccine and more about delivery. Injectable vaccination is labor-intensive, stressful for fish, and often impractical for larvae and fingerlings, while oral vaccination has historically struggled with antigen degradation and weak uptake. This study suggests a workable mucosal delivery approach using a familiar bacterial carrier that preserved particle structure better after hypochlorite inactivation than with live or heat-killed preparations, potentially making mass vaccination more realistic for species such as grouper, and Asian and European seabass. (newswise.com)
What to watch: The team says it has filed three patents and is seeking industry partners for field trials, which will be the real test of whether the platform can translate from controlled challenge work to commercial farm conditions. (newswise.com)
Key facts
- Researchers
- National University of Singapore and Temasek Life Sciences Laboratory
- Target pathogen
- Nervous necrosis virus (NNV), caused by betanodavirus
- Vaccine platform
- Virus-like particles made from the NNV capsid protein inside Lactococcus lactis
- Delivery route
- Oral, mixed into feed
- Study species
- Asian seabass fingerlings
- Study date
- Published January 5, 2026, in Fish & Shellfish Immunology
- Antibody response
- About twofold higher antibody and neutralizing antibody titers than purified VLPs alone
- Challenge result
- About 2.5-log, or about 300-fold, lower brain viral load seven days after challenge
- Development status
- Three patents filed, with industry partners sought for field trials
A Singapore research team says it has cleared one of aquaculture vaccinology’s hardest hurdles: getting an oral fish vaccine to survive the gut and still generate meaningful protection. Scientists at the National University of Singapore, together with Temasek Life Sciences Laboratory, developed an oral nervous necrosis virus vaccine that can be mixed into feed, and reported that it reduced post-challenge brain viral load by about 300-fold in Asian seabass fingerlings. The findings were published in Fish & Shellfish Immunology on January 5, 2026, and highlighted publicly by NUS on June 29, 2026. (newswise.com)
The target is a consequential one. Viral nervous necrosis, caused by betanodavirus, is a major threat in marine and freshwater aquaculture and is associated with substantial losses across many fish species. Reviews published in 2026 describe NNV as a globally significant pathogen with broad host range and considerable genetic diversity, while NUS noted that mortality can approach 100% in larval fish and that survivors may have reduced growth. (pubmed.ncbi.nlm.nih.gov)
What makes this report notable is the delivery strategy. The NUS group used the NNV capsid protein to form noninfectious virus-like particles, then encapsulated those particles inside Lactococcus lactis, a food-grade bacterium often discussed as a mucosal vaccine platform. According to the article abstract, purified VLPs given by injection generated strong humoral responses, but live or heat-inactivated L. lactis carrying VLPs did not protect well when given orally. The breakthrough came when the team inactivated the bacterial carrier with sodium hypochlorite, which preserved VLP encapsulation, solubility, and structural integrity more effectively and improved antigen delivery to the gut immune system. (sciencedirect.com)
The paper’s reported efficacy signals are encouraging, if still early-stage. In Asian seabass fingerlings, the hypochlorite-inactivated oral formulation induced approximately double the antibody and neutralizing antibody titers seen with orally delivered purified VLPs. Challenge testing then showed an approximately 2.5-log reduction in brain viral load seven days after exposure. NUS also framed the platform as potentially relevant to other commercially important species, including grouper, and European and Asian seabass. (sciencedirect.com)
There’s also useful context in the broader literature. Oral fish vaccination is attractive because it reduces handling and labor, but a 2026 review emphasized the same barriers this study tried to solve: antigen breakdown in the digestive tract, inconsistent uptake across the intestinal mucosa, and variable real-world performance. Prior NNV vaccine work has shown promise with injected VLPs, plant-based platforms, yeast systems, inactivated vaccines, and other oral approaches, but the field still lacks simple, scalable options for very young fish. In that sense, the NUS study fits into a larger push to make mucosal immunization practical rather than merely possible. (ddd.uab.cat)
Expert reaction specific to this paper was limited in publicly accessible coverage, but the industry direction is clear from recent reviews and parallel studies. Lactococcus lactis is drawing attention as a safe oral delivery vehicle, and 2026 aquaculture vaccine papers continue to test bacterial, yeast, and encapsulated platforms against viral pathogens in fish. That doesn’t validate commercial readiness on its own, but it does suggest the NUS result is aligned with an active, technically credible area of fish health research rather than a one-off concept. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinarians and fish health teams, this is a reminder that vaccine success in aquaculture often depends as much on delivery engineering as on antigen design. If the formulation proves stable in feed and reproducible in farm settings, it could expand preventive options for hatcheries and juvenile production systems where injection is not feasible. It may also help reduce disease losses earlier in the production cycle, when NNV can be most devastating, though questions around duration of immunity, genotype coverage, dosing schedules, and performance under commercial stressors still need answers. (newswise.com)
What to watch: NUS says the team has filed three patents and plans field trials with industry partners; those studies, along with any regulatory pathway for species-specific commercialization, will determine whether this becomes a practical tool for fish health programs or remains a promising experimental platform. (newswise.com)